Content Dam Diq En Articles Apex360 2016 04 Reliably Anesthesia Free An Interview With Two Solea Laser Dentists Video Leftcolumn Article Thumbnailimage File
Content Dam Diq En Articles Apex360 2016 04 Reliably Anesthesia Free An Interview With Two Solea Laser Dentists Video Leftcolumn Article Thumbnailimage File
Content Dam Diq En Articles Apex360 2016 04 Reliably Anesthesia Free An Interview With Two Solea Laser Dentists Video Leftcolumn Article Thumbnailimage File
Content Dam Diq En Articles Apex360 2016 04 Reliably Anesthesia Free An Interview With Two Solea Laser Dentists Video Leftcolumn Article Thumbnailimage File
Content Dam Diq En Articles Apex360 2016 04 Reliably Anesthesia Free An Interview With Two Solea Laser Dentists Video Leftcolumn Article Thumbnailimage File

'Reliably anesthesia-free': An interview with two Solea laser dentists (VIDEO)

April 18, 2016
Chris Salierno, DDS, interviews Jeffrey Rhode, DDS, and David Fantarella, DMD, about their experiences with Convergent Dental's C02 9.3 micron Solea laser. Topics include cost, ROI, anesthesia-free procedures, multiquadrant dentistry, and learning curve.

Chris Salierno, DDS, interviews Jeffrey Rhode, DDS, and David Fantarella, DMD, about their experiences with Convergent Dental's C02 9.3 micron Solea laser. Topics include cost, ROI, anesthesia-free procedures, multiquadrant dentistry, and learning curve.

At this year's Yankee Dental Meeting, dentists and industry representatives had the opportunity to see the Convergent Dental's Solea laser in action. At a live dentistry event, Jeffrey Rhode, DDS, and David Fantarella, DMD, performed anesthesia-free procedures on patients and then talked to the patients afterward about their experiences.

After the live dentistry event, Dental Economics Chief Editor Chris Salierno, DDS, discussed Solea in-depth with Drs. Rhode and Fantarella. In this interview, the three informally discuss the new frontier of "reliably anesthesia-free dentistry"—which Dr. Fantarella describes as Solea's pain-free experience for approximately 95% of patients.